243 related articles for article (PubMed ID: 38660357)
21. Are Detailed, Patient-level Social Determinant of Health Factors Associated With Physical Function and Mental Health at Presentation Among New Patients With Orthopaedic Conditions?
Bernstein DN; Lans A; Karhade AV; Heng M; Poolman RW; Schwab JH; Tobert DG
Clin Orthop Relat Res; 2023 May; 481(5):912-921. PubMed ID: 36201422
[TBL] [Abstract][Full Text] [Related]
22. Social Determinants of Health and Cancer Pain in the US: Scoping Review.
Youn N; Sorensen J; Howland C; Gilbertson-White S
Clin Nurs Res; 2024 Jun; 33(5):416-428. PubMed ID: 38375791
[TBL] [Abstract][Full Text] [Related]
23. Screening for Social Determinants of Health: Active and Passive Information Retrieval Methods.
Stewart de Ramirez S; Shallat J; McClure K; Foulger R; Barenblat L
Popul Health Manag; 2022 Dec; 25(6):781-788. PubMed ID: 36454231
[TBL] [Abstract][Full Text] [Related]
24. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
Loomba R; Wong VW
Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
[TBL] [Abstract][Full Text] [Related]
25. Social determinants of health screening and intervention: A cystic fibrosis quality improvement process.
Jennings D; List R; Bruschwein H; Compton M; Somerville L; Williamson L; Murray R; Evangelista B; Albon D
Pediatr Pulmonol; 2022 Dec; 57(12):3035-3043. PubMed ID: 36039394
[TBL] [Abstract][Full Text] [Related]
26. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease.
Mellemkjær A; Kjær MB; Haldrup D; Grønbæk H; Thomsen KL
Eur J Intern Med; 2024 Apr; 122():28-34. PubMed ID: 38008609
[TBL] [Abstract][Full Text] [Related]
27. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
28. Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease.
Henin G; Loumaye A; Leclercq IA; Lanthier N
JHEP Rep; 2024 Feb; 6(2):100963. PubMed ID: 38322420
[TBL] [Abstract][Full Text] [Related]
29. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso).
Moreira RO; Valerio CM; Villela-Nogueira CA; Cercato C; Gerchman F; Lottenberg AMP; Godoy-Matos AF; Oliveira RA; Brandão Mello CE; Álvares-da-Silva MR; Leite NC; Cotrim HP; Parisi ER; Silva GF; Miranda PAC; Halpern B; Pinto Oliveira C
Arch Endocrinol Metab; 2023 Nov; 67(6):e230123. PubMed ID: 38048417
[TBL] [Abstract][Full Text] [Related]
30. Healthcare lobbying on upstream social determinants of health in the US.
Counts NZ; Taylor LA; Willison CE; Galea S
Prev Med; 2021 Dec; 153():106751. PubMed ID: 34343593
[TBL] [Abstract][Full Text] [Related]
31. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
[TBL] [Abstract][Full Text] [Related]
32. Inclusion of Rurality and Social Determinants of Health in Documents for the Primary Prevention of Type 2 Diabetes: A Systematic Review.
Tabatabaei Yeganeh HS; Kiliaki SA; Gnanapandithan K; Loor-Torres R; Duran M; Yousufuddin M; Prokop LJ; Vella A; Montori VM; Dugani SB
Metab Syndr Relat Disord; 2024 Jun; 22(5):315-326. PubMed ID: 38708695
[No Abstract] [Full Text] [Related]
33. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
[TBL] [Abstract][Full Text] [Related]
34. Social determinants of health in electronic health records and their impact on analysis and risk prediction: A systematic review.
Chen M; Tan X; Padman R
J Am Med Inform Assoc; 2020 Nov; 27(11):1764-1773. PubMed ID: 33202021
[TBL] [Abstract][Full Text] [Related]
35. Steatotic liver disease, MASLD and risk of chronic kidney disease.
Bilson J; Mantovani A; Byrne CD; Targher G
Diabetes Metab; 2024 Jan; 50(1):101506. PubMed ID: 38141808
[TBL] [Abstract][Full Text] [Related]
36. Exploring the landscape of steatotic liver disease in the general US population.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
[TBL] [Abstract][Full Text] [Related]
37. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
Ramírez-Mejía MM; Jiménez-Gutiérrez C; Eslam M; George J; Méndez-Sánchez N
Hepatol Int; 2024 Feb; 18(1):168-178. PubMed ID: 38127259
[TBL] [Abstract][Full Text] [Related]
38. Universal screening for social determinants of health in pediatric sickle cell disease: A quality-improvement initiative.
Power-Hays A; Li S; Mensah A; Sobota A
Pediatr Blood Cancer; 2020 Jan; 67(1):e28006. PubMed ID: 31571379
[TBL] [Abstract][Full Text] [Related]
39. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes.
Godoy-Matos AF; Valério CM; Silva Júnior WS; de Araujo-Neto JM; Bertoluci MC
Diabetol Metab Syndr; 2024 Jan; 16(1):23. PubMed ID: 38238868
[TBL] [Abstract][Full Text] [Related]
40. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.
Qi X; Li J; Caussy C; Teng GJ; Loomba R
Hepatology; 2024 May; ():. PubMed ID: 38722246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
